Ultimovacs ASA: Mandatory notification of trade by primary insiders
March 07, 2024 17:00 ET
|
Ultimovacs ASA
Oslo, 7 March 2024: Langøya Invest AS, a closely related party of Ketil Fjerdingen, a board member and primary insider in Ultimovacs ASA, has today sold 596,006 shares in the company at an average...
Ultimovacs Announces Topline Results from INITIUM Study Evaluating UV1 Vaccination Added to Ipilimumab and Nivolumab in Patients with Unresectable or Metastatic Malignant Melanoma
March 07, 2024 01:00 ET
|
Ultimovacs ASA
With the 18-month minimum follow-up of the patients in the INITIUM trial, the trial did not meet the primary endpoint of prolonging progression-free survival (PFS). Median PFS was not reached in...
Ultimovacs announces publication of results from NIPU Phase II trial with UV1 vaccination in mesothelioma in European Journal of Cancer
March 02, 2024 12:41 ET
|
Ultimovacs ASA
NON-REGULATORY PRESS RELEASE The NIPU trial is investigating the effect of adding UV1 vaccine to immunotherapy as second-line treatment of pleural mesothelioma. The results were initially...
Ultimovacs Receives EMA Orphan Drug Designation for UV1 Cancer Vaccine for the Treatment of Mesothelioma
February 19, 2024 01:00 ET
|
Ultimovacs ASA
The Orphan Drug Designation (ODD) from the European Medicines Agency (EMA) was granted based on results from the randomized Phase II clinical trial NIPU, which showed improved overall survival...
Ultimovacs ASA Reports Fourth Quarter 2023 Financial Results and Provides General Business Update
February 14, 2024 01:00 ET
|
Ultimovacs ASA
Readout of topline result expected in March 2024 from UV1 randomized Phase II trial INITIUM in Ultimovacs’ lead indication, advanced malignant melanomaTopline result will report primary endpoint of...
Ultimovacs ASA: Invitation to fourth quarter 2023 results webcast presentation
February 08, 2024 02:00 ET
|
Ultimovacs ASA
Oslo, February 8, 2023: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, invites to a webcast presentation of its fourth...
Ultimovacs Receives FDA Fast Track Designation for UV1 Cancer Vaccine for the Treatment of Patients with Unresectable Mesothelioma
February 05, 2024 01:00 ET
|
Ultimovacs ASA
Fast Track designation is granted for UV1 in combination with ipilimumab and nivolumab for the treatment of patients with unresectable malignant pleural mesothelioma to improve overall...
Ultimovacs Updates Timeline for Reporting on Randomized UV1 Phase II Trial INITIUM in Malignant Melanoma; Topline Results expected in March 2024
January 16, 2024 01:00 ET
|
Ultimovacs ASA
Study protocol enables readout of the INITIUM trial after all patients have been followed for a minimum of 18 months, or after 70 patients have progressed or died.As of today, the 70 events...
Ultimovacs ASA: Mandatory notification of trade by primary insider
January 04, 2024 12:57 ET
|
Ultimovacs ASA
Oslo, 4 January 2024: Carlos de Sousa, Chief Executive Officer and primary insider in Ultimovacs ASA, has today bought 500 shares in the company at an average price of NOK 130.00 per share. Following...
Ultimovacs ASA: Mandatory notification of trade by primary insider
January 02, 2024 13:25 ET
|
Ultimovacs ASA
Oslo, 2 January 2024: Carlos de Sousa, Chief Executive Officer and primary insider in Ultimovacs ASA, has today bought 1,500 shares in the company at an average price of NOK 119.75 per share. In...